What is HC Wainwright’s Estimate for FDMT Q2 Earnings?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Investment analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($1.04) per share for the quarter, up from their previous forecast of ($1.10). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($3.79) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($4.08) EPS, FY2027 earnings at ($4.40) EPS, FY2028 earnings at ($4.04) EPS, FY2029 earnings at ($2.65) EPS and FY2030 earnings at ($1.45) EPS.

A number of other research firms have also recently issued reports on FDMT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Chardan Capital reissued a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Barclays started coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Finally, The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a report on Friday. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $10.34 on Wednesday. 4D Molecular Therapeutics has a fifty-two week low of $3.02 and a fifty-two week high of $12.34. The business’s fifty day moving average price is $9.42 and its two-hundred day moving average price is $9.48. The stock has a market capitalization of $540.58 million, a price-to-earnings ratio of -4.02 and a beta of 2.77.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Simplify Asset Management Inc. bought a new position in shares of 4D Molecular Therapeutics during the first quarter worth $656,000. Armistice Capital LLC grew its holdings in shares of 4D Molecular Therapeutics by 76.6% in the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after buying an additional 840,000 shares during the period. Baker BROS. Advisors LP bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at $3,568,000. Landing Point Financial Group LLC acquired a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth about $142,000. Finally, AXQ Capital LP lifted its holdings in shares of 4D Molecular Therapeutics by 138.8% during the 4th quarter. AXQ Capital LP now owns 30,755 shares of the company’s stock valued at $231,000 after purchasing an additional 17,876 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.